Karyopharm Therapeutics Inc. (United States) is listed on the Nasdaq and has a market capitalization of $58.00 million, with shareholders equity totaling $-330.17 million.
The company employs approximately 432 people and operates in the Health Care sector, within the Biotechnology industry.
Over the past 12 months, Karyopharm Therapeutics Inc. reported $146.62 million in revenue, generating net income of $-224.74 million.
Key financial metrics include a P/E ratio of -0.26, a price-to-book (P/B) ratio of -0.18, and a trailing twelve-month dividend yield of 0.00%.
The company trades under the ticker KPTI.